AMENDMENT NO. 1 TO ASSET RETURN AND TERMINATION AGREEMENTAsset Return and Termination Agreement • May 5th, 2017 • Momenta Pharmaceuticals Inc • Biological products, (no disgnostic substances)
This AMENDMENT NO. 1 TO ASSET RETURN AND TERMINATION AGREEMENT (this “Amendment”), effective as of March 20, 2017, amends that certain Asset Return and Termination Agreement, effective December 31, 2016 (the “AR&T Agreement”), by and between Momenta Pharmaceuticals, Inc., a Delaware corporation (“Momenta”), Baxalta Incorporated, a Delaware corporation (“BI”), Baxalta US Inc., a Delaware corporation (“BUSI”), and Baxalta GmbH, a Swiss corporation (“BGMBH” and, together with BI and BUSI, collectively, “Baxalta”). Capitalized terms used herein, but otherwise not defined, shall have the meaning ascribed to them in the AR & T Agreement.
LICENSE AND OPTION AGREEMENT BY AND BETWEEN MOMENTA PHARMACEUTICALS, INC. AND CSL BEHRING RECOMBINANT FACILITY AG DATED AS OF JANUARY 4, 2017License and Option Agreement • May 5th, 2017 • Momenta Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
This License and Option Agreement (the “Agreement”), executed as of January 4, 2017 (the “Execution Date”), is made by and between Momenta Pharmaceuticals, Inc., a Delaware corporation (“Momenta”), with its principal place of business at 675 West Kendall Street, Cambridge, MA 02142 USA, and CSL Behring Recombinant Facility AG, a Swiss company (“CSL”), with its principal place of business at Wankdorfstrasse 10, 3000 Bern 22, Switzerland. Momenta and CSL may each be referred to individually as a “Party” or, collectively, the “Parties”.
